CD47 and diffuse large B-cell lymphoma: In July 2025, Pfizer terminated a Phase II trial of its investigational CD47-targeting fusion protein maplirpacept (PF-07901801) in combination with tafasitamab and lenalidomide for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), citing an inability to recruit the planned number of subjects after enrolling only six patients since August 2023.